HDAC9 and ovarian carcinoma: Consistently, it has been shown that class I HDACs are abundantly distributed and widely expressed in ovarian cancer tissues, whereas abnormal HDAC expression is conserded to be closely associated with adverse response to chemotherapy [26, 27].